For many decades, aspirin has been one of the most widely used medicines for protecting the heart. Doctors often prescribe it to people with heart disease to reduce the risk of heart attacks and strokes. However, a new study suggests that another group of medications may offer even better protection for some patients with coronary artery disease.
The research was conducted by scientists from the Cardiocentro Ticino Foundation in Switzerland and led by Professor Marco Valgimigli. The findings were published in the medical journal European Heart Journal.
The results suggest that a class of drugs known as P2Y12 inhibitors could provide stronger protection against heart attacks and strokes than aspirin, without increasing the risk of serious bleeding.
Heart disease remains the leading cause of death worldwide. One of the most common forms is coronary artery disease. This condition occurs when the arteries that supply blood to the heart become narrowed or blocked by fatty deposits called plaques. When blood flow to the heart is reduced or suddenly blocked, it can lead to a heart attack.
To prevent these dangerous events, doctors often prescribe medications that stop blood cells called platelets from sticking together and forming clots. These medicines are known as antiplatelet drugs.
Aspirin has long been the most common antiplatelet medication. It works by reducing the ability of platelets to clump together. Because of this effect, aspirin helps prevent clots from forming in the arteries. For many years, it has been considered the standard long‑term treatment for people who have already experienced heart problems.
However, modern heart treatment often involves a combination of medications. Many patients who experience acute coronary syndrome, a serious condition that includes heart attacks and unstable chest pain, are first treated with a therapy called dual antiplatelet therapy.
This treatment usually combines aspirin with another type of antiplatelet drug known as a P2Y12 inhibitor.
Common P2Y12 inhibitors include clopidogrel, prasugrel, and ticagrelor. These drugs block a specific receptor on platelets that normally helps them become sticky and form clots. By blocking this signal, the drugs make it harder for dangerous clots to develop.
After patients complete the initial period of dual therapy, they are often advised to continue taking aspirin alone for the rest of their lives. This has been the standard medical practice for many years.
Earlier research had hinted that clopidogrel, one of the P2Y12 inhibitors, might work slightly better than aspirin in some patients. The new study aimed to examine this question more carefully using a much larger group of patients.
In the study, researchers analyzed data from 24,325 people who had been diagnosed with coronary artery disease. The participants were divided into two groups. One group took a P2Y12 inhibitor as their long‑term medication, while the other group took aspirin.
The scientists followed these patients for an average of about 557 days, which is a little more than a year and a half. During this time, they carefully tracked major health events, including heart attacks, strokes, and serious bleeding complications.
When the researchers compared the two groups, they found an important difference. Patients taking P2Y12 inhibitors had a lower overall risk of heart attacks and strokes compared with those taking aspirin.
Specifically, the combined risk of heart attack and stroke was reduced by about 12 percent among patients taking P2Y12 inhibitors. The reduction was mainly driven by a significant decrease in heart attacks. The risk of heart attack alone was about 23 percent lower in the P2Y12 inhibitor group.
Another important finding involved safety. Many doctors worry that stronger blood‑thinning medicines may increase the risk of dangerous bleeding. Surprisingly, the study showed that major bleeding risks were similar between the two groups.
Even more encouraging, patients taking P2Y12 inhibitors experienced fewer cases of certain types of bleeding. In particular, there were fewer cases of gastrointestinal bleeding, which occurs in the stomach or intestines. There were also fewer hemorrhagic strokes, which are strokes caused by bleeding in the brain.
These results suggest that P2Y12 inhibitors may provide stronger protection against heart problems while maintaining a similar safety profile compared with aspirin.
The findings are important because aspirin can sometimes irritate the stomach lining and increase the risk of bleeding in the digestive system or brain. For patients who already have a higher risk of these complications, alternative treatments may be helpful.
Professor Valgimigli explained that the study highlights the importance of tailoring treatments to each patient’s individual risk. Not every patient with heart disease is the same, and the best medication may depend on a person’s overall health, bleeding risk, and medical history.
While aspirin will likely remain an important medicine for many people, the new evidence suggests that P2Y12 inhibitors could become a preferred long‑term treatment option for certain patients with coronary artery disease.
Doctors may increasingly consider continuing a P2Y12 inhibitor instead of switching patients to aspirin after the initial period of dual antiplatelet therapy.
Researchers emphasize that patients should never stop or change their medications without speaking to their doctor first. Treatment decisions should always be made with guidance from a healthcare professional who understands the patient’s medical history.
The study adds to growing scientific evidence that heart disease treatment may benefit from more personalized approaches. As new research continues, doctors hope to improve prevention strategies so that patients can reduce their risk of heart attacks and strokes while avoiding unnecessary side effects.
For millions of people living with coronary artery disease, these findings may open the door to safer and more effective long‑term treatments in the future.
If you care about heart health, please read studies about how eating eggs can help reduce heart disease risk, and herbal supplements could harm your heart rhythm.
For more health information, please see recent studies about how drinking milk affects risks of heart disease and cancer, and results showing strawberries could help prevent Alzheimer’s disease.
Copyright © 2026 Knowridge Science Report. All rights reserved.
